As mentioned above, in TNBC patients, the micropeptide ASRPS inhibited tumor angiogenesis by modulating the STAT3/VEGF pathway, and intratumoral injection of ASRPS also prolonged the survival time in TNBC mouse models. Here, STAT3 is linked to neoplasm.